Literature DB >> 32534104

Pharmacokinetic profile of Perfluorobutane Sulfonate and activation of hepatic nuclear receptor target genes in mice.

Christopher Lau1, Jason Rumpler2, Kaberi P Das3, Carman R Wood3, Judith E Schmid3, Mark J Strynar4, John F Wambaugh5.   

Abstract

Per- and polyfluoroalkyl substances (PFAS) are organic chemicals with wide industrial and consumer uses. They are found ubiquitously at low levels in the environment and are detectable in humans and wildlife. Perfluorobutane Sulfonate (PFBS) is a short-chained PFAS used to replace perfluorooctane sulfonate in commerce. In general, the rate of clearance for the short-chained PFAS is faster than that for the long-chained congeners. This study evaluated the pharmacokinetic properties of PFBS and its hepatic transcriptional responses in CD-1 mice. Males and females were given PFBS by oral gavage at 30 or 300 mg/kg; controls received 0.5 % Tween-20 vehicle. Trunk blood was collected at 0.5, 1, 2, 4, 8, 16 and 24 h thereafter; liver and kidney were also harvested. Serum and tissue concentrations of PFBS were determined by HPLC-MS-MS. Expression of several hepatic nuclear receptor target genes was determined by qPCR. The half-life of PFBS was estimated as 5.8 h in the males and 4.5 h in the females. Tmax was reached within 1-2 h. Volume of distribution was similar between the two sexes (0.32-0.40 L/kg). The rate of PFBS clearance was linear with exposure doses. Within 24 h, serum PFBS declined to less than 5 % of Cmax. PFBS was detected in liver or kidney, although tissue levels of the chemical were only a fraction of those in serum. At 24 h after administration of 300 mg/kg PFBS, elevated expression of several hepatic genes targeted for PPARα, PPARy, and PXR but not by AhR, LXR or CAR was observed, with responses indistinguishable between males and females. Little to no transcriptional response was seen with the 30 mg/kg dose. The short serum half-lives of PFBS (4-5 h) in mice were comparable to those reported in rats. Although detection of PFBS in liver was low compared to that in serum even at the 300 mg/kg dose, the tissue level was sufficient to activate several hepatic nuclear receptors, which may represent an acute response to the chemical at a high dose.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Mouse; Perfluorobutane sulfonate; Pharmacokinetics

Mesh:

Substances:

Year:  2020        PMID: 32534104      PMCID: PMC9148184          DOI: 10.1016/j.tox.2020.152522

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.571


  32 in total

1.  The effects of perfluorooctanoate on high fat diet induced non-alcoholic fatty liver disease in mice.

Authors:  Xilin Li; Zemin Wang; James E Klaunig
Journal:  Toxicology       Date:  2019-01-31       Impact factor: 4.221

2.  Elimination kinetics of perfluorohexanoic acid in humans and comparison with mouse, rat and monkey.

Authors:  Mark H Russell; Helena Nilsson; Robert C Buck
Journal:  Chemosphere       Date:  2013-09-16       Impact factor: 7.086

3.  Comparative pharmacokinetics of perfluorononanoic acid in rat and mouse.

Authors:  Katoria Tatum-Gibbs; John F Wambaugh; Kaberi P Das; Robert D Zehr; Mark J Strynar; Andrew B Lindstrom; Amy Delinsky; Christopher Lau
Journal:  Toxicology       Date:  2011-01-13       Impact factor: 4.221

4.  Comparative pharmacokinetics of perfluorohexanesulfonate (PFHxS) in rats, mice, and monkeys.

Authors:  Maria Sundström; Shu-Ching Chang; Patricia E Noker; Gregory S Gorman; Jill A Hart; David J Ehresman; Åke Bergman; John L Butenhoff
Journal:  Reprod Toxicol       Date:  2011-08-11       Impact factor: 3.143

5.  Perfluorobutanesulfonic acid (PFBS) potentiates adipogenesis of 3T3-L1 adipocytes.

Authors:  Weipeng Qi; John M Clark; Alicia R Timme-Laragy; Yeonhwa Park
Journal:  Food Chem Toxicol       Date:  2018-07-18       Impact factor: 6.023

6.  A comparison of the pharmacokinetics of perfluorobutanesulfonate (PFBS) in rats, monkeys, and humans.

Authors:  Geary W Olsen; Shu-Ching Chang; Patricia E Noker; Gregory S Gorman; David J Ehresman; Paul H Lieder; John L Butenhoff
Journal:  Toxicology       Date:  2008-11-19       Impact factor: 4.221

7.  Tissue distribution of 35S-labelled perfluorobutanesulfonic acid in adult mice following dietary exposure for 1-5 days.

Authors:  Jasna Bogdanska; Maria Sundström; Ulrika Bergström; Daniel Borg; Manuchehr Abedi-Valugerdi; Åke Bergman; Joseph DePierre; Stefan Nobel
Journal:  Chemosphere       Date:  2013-11-14       Impact factor: 7.086

8.  The biochemical toxicity of perfluorodecanoic acid in the mouse is different from that of 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Authors:  D W Brewster; L S Birnbaum
Journal:  Toxicol Appl Pharmacol       Date:  1989-07       Impact factor: 4.219

9.  Evaluation of perfluoroalkyl acid activity using primary mouse and human hepatocytes.

Authors:  Mitchell B Rosen; Kaberi P Das; Carmen R Wood; Cynthia J Wolf; Barbara D Abbott; Christopher Lau
Journal:  Toxicology       Date:  2013-04-06       Impact factor: 4.221

10.  Toxicokinetics of perfluorobutane sulfonate (PFBS), perfluorohexane-1-sulphonic acid (PFHxS), and perfluorooctane sulfonic acid (PFOS) in male and female Hsd:Sprague Dawley SD rats after intravenous and gavage administration.

Authors:  M C Huang; A L Dzierlenga; V G Robinson; S Waidyanatha; M J DeVito; M A Eifrid; C A Granville; S T Gibbs; C R Blystone
Journal:  Toxicol Rep       Date:  2019-06-28
View more
  2 in total

Review 1.  Metabolism-Disrupting Chemicals and the Constitutive Androstane Receptor CAR.

Authors:  Jenni Küblbeck; Jonna Niskanen; Paavo Honkakoski
Journal:  Cells       Date:  2020-10-15       Impact factor: 6.600

2.  Internal Relative Potency Factors for the Risk Assessment of Mixtures of Per- and Polyfluoroalkyl Substances (PFAS) in Human Biomonitoring.

Authors:  Wieneke Bil; Marco J Zeilmaker; Bas G H Bokkers
Journal:  Environ Health Perspect       Date:  2022-07-26       Impact factor: 11.035

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.